Histidine Supplementation for Antitumor Immunity in Colorectal Cancer
ConditionColorectal Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorJing-yuan Fang, MD, Ph. D
About this trial
The goal of this clinical study is to learn whether oral histidine supplementation may be safely used to support antitumor immune function during standard colorectal cancer treatment.
Participants with colorectal cancer in the supplementation group will:
Take 2g oral histidine once daily during standard colorectal cancer treatment; Provide blood samples before and after supplementation; Attend regular follow-up visits for laboratory tests, safety assessment, and treatment evaluation.
Eligibility criteria
Qualifiers
Patients aged 18-80 years, regardless of sex.
Body mass index (BMI) ≥18.5.
NRS-2002 score <3.
Diagnosed with stage II or higher colorectal cancer who require pharmacological intervention.
Disqualifiers
Participation in other interventional clinical trials (including drugs, nutritional supplements, medical devices, etc.) within 4 weeks prior to enrollment.
Presence of ascites, severe diarrhea, intractable vomiting, severe malabsorption syndrome, paralysis, mechanical intestinal obstruction, or active gastrointestinal bleeding.
Allergy to sample components.
Current use of other nutritional supplements that may affect the validity and effectiveness of the study results.
Trial design
Treatments tested in this trial
- Histidine
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Jing-yuan Fang, MD, Ph. D
Lead sponsor
Shanghai Jiao Tong University School of Medicine
Sponsor institution
Shanghai Punan Hospital of Pudong New District
Collaborator
Source ClinicalTrials.gov